Nestlé Balances Infant-Formula Recall Risk Against Coffee-Led Growth - ad-hoc-news.de
Article excerpt
Nestlé's investment case now hinges on two very different questions: whether a recall of certain infant-formula batches stays contained, and whether the group's coffee business can keep driving growth while that product-safety risk hangs over the stock. Confirmed illnesses linked to the affected batches have not been reported, a detail that leaves room for a more favorable outcome even as the international scope of the recall signals a risk worth taking seriously. Bernstein Research kept Nestlé at "Market-Perform" on Tuesday with a price target of 77 CHF. According to media reports, the note offered no specific explanation for the recent share-price move. The stock was up 1.5% at €94.88 today. The analyst action was not a fresh downgrade - the house reaffirmed its rating, and the note documents no further change to the price target. Media reports on Tuesday identified coffee as one of the group's strongest growth categories, with both Nescafé and Nespresso posting gains. That operating momentum gives investors a business anchor against which to weigh the recall. Nestlé has also confirmed its full-year guidance, a figure that points to a growth base provided the fallout from the recall does not materially hamper further development. For anyone betting on that growth, the recall has to be factored in. A constructive view requires both a sound operating business and a...
Keep reading with a free account
The rest of this article, and every signal for Nestle, is in your free account.
Extracted from this sentence
The European launch is planned for between November 2026 and early 2027.
